Increased extent of myocardial fibrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyarrhythmias

Journal of Cardiology

Volumn 66, Issue 1, 2015, Pages 63-68

  Fujita, Takashi ^a   Konno, Tetsuo ^a,b   Yokawa, Junichiro ^a,c   Masuta, Eiichi ^a   Nagata, Yoji ^a   Fujino, Noboru ^a   Funada, Akira ^a   Hodatsu, Akihiko ^a   Kawashiri, Masa aki ^a   Yamagishi, Masakazu ^a,b   Hayashi, Kenshi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Fukui Prefectural Hospital   (Japan)

Author keywords

Hypertrophic cardiomyopathy; Magnetic resonance imaging; Myocardial fibrosis; Ventricular arrhythmia

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL EVALUATION; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEART MUSCLE FIBROSIS; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PREDICTIVE VALUE; RADIODIAGNOSIS; SARCOMERE; COMPLICATION; EVALUATION STUDY; FIBROSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

CONTRAST MEDIUM; GADOLINIUM PENTETATE;

CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TACHYCARDIA, VENTRICULAR;

EID: 84930892379     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.10.002     Document Type: Article

References (39)

1. Maron B.J., Maron M.S., Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012, 60:705-715.
2. Kawashiri M.A., Hayashi K., Konno T., Fujino N., Ino H., Yamagishi M. Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels 2014, 29:129-141.
3. Spirito P., Seidman C.E., McKenna W.J., Maron B.J. The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336:775-785.
4. Fujita T., Fujino N., Anan R., Tei C., Kubo T., Doi Y., Kinugawa S., Tsutsui H., Kobayashi S., Yano M., Asakura M., Kitakaze M., Komuro I., Konno T., Hayashi K., et al. Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy: results from multicenter registration in Japan. JACC Heart Fail 2013, 1:459-466.
5. Monserrat L., Elliott P.M., Gimeno J.R., Sharma S., Penas-Lado M., McKenna W.J. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003, 42:873-879.
6. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287:1308-1320.
7. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., Naidu S.S., Nishimura R.A., Ommen S.R., Rakowski H., Seidman C.E., Towbin J.A., Udelson J.E., Yancy C.W. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011, 58:e212-e260.
8. Fluechter S., Kuschyk J., Wolpert C., Doesch C., Veltmann C., Haghi D., Schoenberg S.O., Sueselbeck T., Germans T., Streitner F., Borggrefe M., Papavassiliu T. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2010, 12:30.
9. Payá E., Marín F., González J., Gimeno J.R., Feliu E., Romero A., Ruiz-Espejo F., Roldán V., Climent V., de la Morena G., Valdés M. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications. J Card Fail 2008, 14:414-419.
10. Adabag A.S., Maron B.J., Appelbaum E., Harrigan C.J., Buros J.L., Gibson C.M., Lesser J.R., Hanna C.A., Udelson J.E., Manning W.J., Maron M.S. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
11. Maron B.J., McKenna W.J., Danielson G.K., Kappenberger L.J., Kuhn H.J., Seidman C.E., Shah P.M., Spencer W.H., Spirito P., Ten Cate F.J., Wigle E.D. Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003, 42:1687-1713.
12. Fujino N., Konno T., Hayashi K., Hodatsu A., Fujita T., Tsuda T., Nagata Y., Kawashiri M.A., Ino H., Yamagishi M. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy. Clin Cardiol 2013, 36:160-165.
13. American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American College of Chest Physicians, Douglas P.S., Garcia M.J., Haines D.E., Lai W.W., et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr 2011, 24:229-267.
14. Harris K.M., Spirito P., Maron M.S., Zenovich A.G., Formisano F., Lesser J.R., Mackey-Bojack S., Manning W.J., Udelson J.E., Maron B.J. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006, 114:216-225.
15. Kramer C.M., Barkhausen J., Flamm S.D., Kim R.J., Nagel E. Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 2008, 10:35.
16. Bruder O., Wagner A., Jensen C.J., Schneider S., Ong P., Kispert E.M., Nassenstein K., Schlosser T., Sabin G.V., Sechtem U., Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
17. Konno T., Hayashi K., Fujino N., Nagata Y., Hodatsu A., Masuta E., Sakata K., Nakamura H., Kawashiri M.A., Yamagishi M. High sensitivity of late gadolinium enhancement for predicting microscopic myocardial scarring in biopsied specimens in hypertrophic cardiomyopathy. PLOS ONE 2014, 9:e101465.
18. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., Pennell D.J., Rumberger J.A., Ryan T., Verani M.S., American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002, 105:539-542.
19. Maron B.J., Roberts W.C. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979, 59:689-706.
20. Varnava A.M., Elliott P.M., Sharma S., McKenna W.J., Davies M.J. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000, 84:476-482.
21. Ho C.Y., Abbasi S.A., Neilan T.G., Shah R.V., Chen Y., Heydari B., Cirino A.L., Lakdawala N.K., Orav E.J., González A., López B., Díez J., Jerosch-Herold M., Kwong R.Y. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging 2013, 6:415-422.
22. Moon J., Hong Y.J., Kim Y.J., Shim C.Y., Jang Y., Chung N., Cho S.Y., Ha J.W. Extent of late gadolinium enhancement on cardiovascular magnetic resonance imaging and its relation to left ventricular longitudinal functional reserve during exercise in patients with hypertrophic cardiomyopathy. Circ J 2013, 77:1742-1749.
23. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012, 5:370-377.
24. Todiere G., Aquaro G.D., Piaggi P., Formisano F., Barison A., Masci P.G., Strata E., Bacigalupo L., Marzilli M., Pingitore A., Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2012, 60:922-929.
25. Ellims A.H., Iles L.M., Ling L.H., Hare J.L., Kaye D.M., Taylor A.J. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson 2012, 14:76.
26. Moravsky G., Ofek E., Rakowski H., Butany J., Williams L., Ralph-Edwards A., Wintersperger B.J., Crean A. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging 2013, 6:587-596.
27. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., Petrou M., Pennell D.J. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
28. O'Hanlon R., Grasso A., Roughton M., Moon J.C., Clark S., Wage R., Webb J., Kulkarni M., Dawson D., Sulaibeekh L., Chandrasekaran B., Bucciarelli-Ducci C., Pasquale F., Cowie M.R., McKenna W.J., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
29. Müller K.A., Müller I., Kramer U., Kandolf R., Gawaz M., Bauer A., Zuern C.S. Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study. PLOS ONE 2013, 8:e57077.
30. Watkins H., McKenna W.J., Thierfelder L., Suk H.J., Anan R., O'Donoghue A., Spirito P., Matsumori A., Moravec C.S., Seidman J.G., Seidman C.E. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995, 332:1058-1064.
31. Niimura H., Bachinski L.L., Sangwatanaroj S., Watkins H., Chudley A.E., McKenna W., Kristinsson A., Roberts R., Sole M., Maron B.J., Seidman J.G., Seidman C.E. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998, 338:1248-1257.
32. Konno T., Chang S., Seidman J.G., Seidman C.E. Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 2010, 25:205-209.
33. Kim R.J., Fieno D.S., Parrish T.B., Harris K., Chen E.L., Simonetti O., Bundy J., Finn J.P., Klocke F.J., Judd R.M. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100:1992-2002.
34. Kim R.J., Wu E., Rafael A., Chen E.L., Parker M.A., Simonetti O., Klocke F.J., Bonow R.O., Judd R.M. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000, 343:1445-1453.
35. Hen Y., Iguchi N., Utanohara Y., Takada K., Machida H., Takayama M., Sumiyoshi T. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 2014, 78:929-937.
36. Wolf C.M., Moskowitz I.P., Arno S., Branco D.M., Semsarian C., Bernstein S.A., Peterson M., Maida M., Morley G.E., Fishman G., Berul C.I., Seidman C.E., Seidman J.G. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci U S A 2005, 102:18123-18128.
37. Mahadavan G., Nguyen T.H., Horowitz J.D. Brain natriuretic peptide: a biomarker for all cardiac disease. Curr Opin Cardiol 2014, 29:160-166.
38. Karaahmet T., Tigen K., Dundar C., Pala S., Guler A., Kilicgedik A., Cevik C., Mahmutyazicioglu K., Isiklar I., Basaran Y. The effect of cardiac fibrosis on left ventricular remodeling, diastolic function, and N-terminal pro-B-type natriuretic peptide levels in patients with nonischemic dilated cardiomyopathy. Echocardiography 2010, 27:954-960.
39. JCS Joint Working Group Guidelines for risks and prevention of sudden cardiac death (JCS 2010): digest version. Circ J 2012, 76:489-507.